| payload |
{"created_at":"2026-04-10T03:04:31.796 {"created_at":"2026-04-10T03:04:31.796915+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:f3e641ac05967221","evidence_event_ids":["evt_ac9041362338"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1831828/0001140361-26-014006.txt","as_of":"2026-04-10T03:04:31.796915+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1831828/0001140361-26-014006.txt","company":"Vera Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1831828/0001140361-26-014006.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_1274fb729423dcb2","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1831828/0001140361-26-014006.txt","content_type":"text/plain","enriched_at":"2026-04-10T03:16:51.952340+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1831828/0001140361-26-014006.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1831828/0001140361-26-014006.txt","source_event_id":"evt_ac9041362338","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEFA14A","fp":"9c479d9ce710254b","kind":"sec_filing","published_at":"20260409","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2026-04-09","20260409"],"entities":[{"asset_class":"equity","name":"Vera Therapeutics, Inc.","relevance":"high","symbol":"","type":"issuer"}],"event_type":"listing","information_gaps":["The provided text does not include the substantive content of the DEFA14A (e.g., what changes were made vs prior proxy materials), beyond the form metadata and that it is \u201cdefinitive additional materials.\u201d","No explicit \u201cAmendment No.\u201d number or description of the specific changes is present in the provided excerpt.","No prior-known-state comparison details are included in the provided text, so the exact delta vs earlier filings cannot be determined from this signal alone."],"key_facts":["SEC accession number: 0001140361-26-014006 (as shown in the provided text).","Conformed submission type: DEFA14A.","Filed as of date / date as of change: 20260409 (as shown in the provided text).","Filing indicates it is a Schedule 14A information proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934.","Box checked: \u201cDefinitive Additional Materials\u201d (\u2612 Definitive Additional Materials).","Payment of filing fee: \u201cNo fee required\u201d (\u2612 No fee required).","Issuer/registrant name shown: Vera Therapeutics, Inc.","SEC file number shown: 001-40407.","Central Index Key (CIK) shown: 0001831828."],"numeric_claims":[],"primary_claim":"Vera Therapeutics, Inc. filed Form DEFA14A (definitive additional materials) with the SEC on 2026-04-09.","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"Vera Therapeutics, Inc. filed a definitive additional proxy statement on Form DEFA14A with the SEC on 2026-04-09. The filing is identified as a definitive additional materials submission (no fee required).","topics":["SEC filing","proxy statement","DEFA14A","definitive additional materials"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEFA14A \u00b7 Vera Therapeutics, Inc. \u00b7 Filed 20260409","ticker":"VERA","tickers":["VERA"],"title":"VERA filed DEFA14A","url":"https://www.sec.gov/Archives/edgar/data/1831828/0001140361-26-014006.txt"}}... |